Anderson K, Ismaila N, Flynn PJ, et al. Role of bone-modifying agents in multiple myeloma: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2018 Mar;36(8):812-818. doi: 10.1200/JCO.2017.76.6402. PMID: 29341831
Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6. PMID: 27511158
Michels TC, Petersen KE. Multiple myeloma: Diagnosis and treatment. Am Fam Physician. 2017 Mar;95(6):373-383. PMID: 28318212
Moreau P, San Miguel J, Sonneveld P, et al; ESMO Guidelines Committee. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul;28(Suppl 4):iv52-iv61. doi: 10.1093/annonc/mdx096. PMID: 28453614
Rajkumar SV. Clinical features, laboratory manifestations, and diagnosis of multiple myeloma. UptoDate. https://www.uptodate.com. Feb 2018.
Rajkumar SV. Multiple myeloma: overview of management. UpToDate. https://www.uptodate.com. 10 Aug 2020. Accessed 11 May 2018.
Rajkumar SV. Pathobiology of multiple myeloma. UptoDate. https://www.uptodate.com. Nov 2017.
Rajkumar SV. Multiple myeloma: treatment of relapsed or refractory disease. UpToDate. https://www.uptodate.com. 25 Aug 2020. Accessed 11 May 2018.
Tan D, Chng WJ, Chou T, et al. Management of multiple myeloma in Asia: resource-stratified guidelines. Lancet Oncol. 2013 Nov;14(12):e571-e581. doi: 10.1016/S1470-2045(13)70404-2. PMID: 24176575
de Mel S, Chen Y, Gopalakrishnan SK, et al. The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma. Singapore Med J. 2017 Feb;58(2):55-71. doi: 10.11622/smedj.2016150. PMID: 27609508
Hillengass J, Usmani S, Rajkumar SV, et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019 Jun;20(6):e302-e312. doi: 10.1016/S1470-2045(19)30309-2. PMID: 31162104
Mikhael J, Ismaila N, Cheung MC, et al. Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. J Clin Oncol. 2019 May;37(14):1228-1263. doi: 10.1200/JCO.18.02096. PMID: 30932732
Bergstrom DJ, Kotb R, Louzada ML, et al. Consensus guidelines on the diagnosis of multiple myeloma and related disorders: recommendations of the Myeloma Canada Research Network Consensus Guidelines Consortium. Clin Lymphoma Myeloma Leuk. 2020 Jul;20(7):e352-e367. doi: 10.1016/j.clml.2020.01.017. PMID: 32249195
Cancer Therapy Advisor. Multiple myeloma treatment regimens. Cancer Therapy Advisor. https://www.cancertherapyadvisor.com/. Oct 2017.
Rajkumar SV. Multiple myeloma: regimens used for relapsed or refractory disease. UpToDate. https://www.uptodate.com. 25 Aug 2020.
Rajkumar SV. Multiple myeloma: selection of initial chemotherapy for symptomatic disease. UpToDate. https://www.uptodate.com. 02 Oct 2020.
Laubach JP. Multiple myeloma: clinical features, laboratory manifestations, and diagnosis. UpToDate. https://www.uptodate.com. 13 Aug 2020.
Dimopoulos MA, Moreau P, Terpos E, et al; EHA Guidelines Committee; ESMO Guidelines Committee. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2021 Mar;32(3):309-322. doi: 10.1016/j.annonc.2020.11.014. PMID: 33549387
D'Agostino M, Cairns DA, Lahuerta JJ, et al. Second Revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project. J Clin Oncol. 2022 Oct;40(29):3406-3418. doi: 10.1200/JCO.21.02614. PMID: 35605179
Laubach JP. Multiple myeloma: overview of management. UpToDate. https://www.uptodate.com/. 14 Jun 2024.
Lin Y, Qiu L, Usmani S, et al. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee. Lancet Oncol. 2024 Aug;25(8):e374-e387. doi: 10.1016/S1470-2045(24)00094-9. PMID: 38821074
Costa LJ, Banerjee R, Mian H, et al. International Myeloma Working Group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma. Leukemia. 2025 Mar;39(3):543-554. doi: 10.1038/s41375-024-02482-6. PMID: 39870767
Hashmi H, Kumar A, Kharfan-Dabaja MA, et al. ASTCT Committee on practice guidelines survey on evaluation and management of relapsed/refractory multiple myeloma after failure of chimeric antigen receptor T cell therapy. Transplant Cell Ther. 2024 Aug;30(8):750-759. doi: 10.1016/j.jtct.2024.04.007. PMID: 38615990
Khan S, Bergstrom DJ, Côté J, et al. First line treatment of newly diagnosed transplant eligible multiple myeloma recommendations from a Canadian Consensus Guideline Consortium. Clin Lymphoma Myeloma Leuk. 2025 Mar;25(3):e151-e172. doi: 10.1016/j.clml.2024.10.012. PMID: 39567294
Laubach JP. Multiple myeloma: treatment of second or later relapse. UpToDate. https://www.uptodate.com. 28 Apr 2025.
National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN guidelines): multiple myeloma. Version 3.2026. NCCN. https://www.nccn.org/. 03 Nov 2025.
Dimopoulos MA, Terpos E, Boccadoro M, et al. EHA-EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. Nat Rev Clin Oncol. 2025 Sep;22(9):680-700. doi: 10.1038/s41571-025-01041-x. PMID: 40624367
National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN guidelines): multiple myeloma. Version 2.2027. NCCN. https://www.nccn.org/. 24 Sep 2026.
